NextCure Launches Early-Stage Study For NC762 In Solid Tumor Settings

NextCure Inc NXTC has initiated the clinical trial of its third product candidate, NC762, a humanized B7-H4 monoclonal antibody.
The Phase 1 dose-escalation portion of this Phase 1/2 open-label trial will evaluate the safety and tolerability of NC762 in patients with advanced or metastatic solid tumors and determine its maximum tolerated dose.
After a recommended dose for the Phase 2 portion of the trial is determined, NC762 will be evaluated in select tumor types.
A B7-H4 Immunohistochemistry (IHC) assay has been developed and will be used for patient selection in Phase 2.
Price Action: NXTC shares closed at $7.89 on Tuesday.